



Disclosure of total number of voting rights and number of shares in the capital at March 31, 2011

Paris, April 8, 2011 – Pursuant to article L.233-8 II of the *Code de commerce* (the French Commercial Code) and article 223-16 of the *Règlement général de l’Autorité des Marchés Financiers* (Regulation of the French stock market authority):

Date	Total number of outstanding shares	Total number of voting rights
March 31, 2011	13, 536,072	Theoretical number of voting rights: 13, 536,072 (including treasury shares) Number of real voting rights: 13, 497,119 (without treasury shares)

About BioAlliance Pharma

Dedicated to cancer and supportive care – cancer related pathologies, chemotherapy and radiotherapy induced complications and opportunistic infections in immunocompromised patients – BioAlliance conceives and develops innovative products, especially in the hospital setting and for orphan or rare diseases.

BioAlliance Pharma SA

Dominique Costantini, President and CEO
 Tel.: +33 1 45 58 76 01
dominique.costantini@bioalliancepharma.com

ALIZE RP

Caroline Carmagnol
 Tel.: +33 6 64 18 99 59
caroline@alizerp.com

Nicolas Fellmann, CFO
 Tel.: +33 1 45 58 71 00
nicolas.fellmann@bioalliancepharma.com